BI836845, mAb targeted against IGF-1/2, showed encouraging results in preclinical models: it reduced the proliferation of human cell lines derived from different cancer types, inhibited tumor growth in a xenograft model and had additive effect in combination with rapamycin [48]; hence, it is now in clinical trial phase II for metastatic breast cancer patients (www.clinicaltrials.gov, NCT02123823). Here, IGF1 is linked to neoplasm.